These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25707197)

  • 1. [Study toward practical use of oligonucleotide therapeutics].
    Inoue T; Yoshida T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):13-5. PubMed ID: 25707197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
    Ito MK
    Ann Pharmacother; 2007 Oct; 41(10):1669-78. PubMed ID: 17848425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mipomersen sodium: first global approval.
    Hair P; Cameron F; McKeage K
    Drugs; 2013 Apr; 73(5):487-93. PubMed ID: 23564617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen.
    Am J Cardiovasc Drugs; 2010; 10(4):271-9. PubMed ID: 20653334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B.
    Geary RS; Baker BF; Crooke ST
    Clin Pharmacokinet; 2015 Feb; 54(2):133-46. PubMed ID: 25559341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Collaborative study on regulatory science for facilitating clinical development of gene therapy products for genetic diseases].
    Uchida E; Igarashi Y; Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):10-2. PubMed ID: 25707196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RNA: A Transformative Therapeutic Strategy.
    Yin W; Rogge M
    Clin Transl Sci; 2019 Mar; 12(2):98-112. PubMed ID: 30706991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
    Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
    EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen.
    Li Z; Hard ML; Grundy JS; Singh T; von Moltke LL; Boltje I
    J Cardiovasc Pharmacol; 2014 Aug; 64(2):164-71. PubMed ID: 24691275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Clinical Applications of Antisense Oligonucleotide Gapmers.
    Chan L; Yokota T
    Methods Mol Biol; 2020; 2176():21-47. PubMed ID: 32865780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
    Burnett JR
    Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotide-based pharmaceuticals: Non-clinical and clinical safety signals and non-clinical testing strategies.
    Mustonen EK; Palomäki T; Pasanen M
    Regul Toxicol Pharmacol; 2017 Nov; 90():328-341. PubMed ID: 28966105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Oligonucleotide Therapeutics in Oncology.
    Xiong H; Veedu RN; Diermeier SD
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligonucleotide therapeutics: chemistry, delivery and clinical progress.
    Sharma VK; Watts JK
    Future Med Chem; 2015; 7(16):2221-42. PubMed ID: 26510815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.
    Debacker AJ; Voutila J; Catley M; Blakey D; Habib N
    Mol Ther; 2020 Aug; 28(8):1759-1771. PubMed ID: 32592692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.